Next Article in Journal
Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma
Next Article in Special Issue
Efficacy of Supportive Care for Radiodermatitis in Patients with Head and Neck Cancer: Supplementary Analysis of an Exploratory Phase II Trial
Previous Article in Journal
Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma
Previous Article in Special Issue
Metallic Artifact Reduction in Midfacial CT Scans Using Patient-Specific Polymer Implants Enhances Image Quality
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 13
Issue 2
10.3390/jpm13020361
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Differences between Squamous Cell Carcinomas of the Base of the Tongue and the Tonsils in Prevalence of HPV16 Infection, Its Type, and Clinical Features

by
Beata Biesaga
1,*,
Anna Mucha-Małecka
2,
Anna Janecka-Widla
1 and
Krzysztof Małecki
3
1
Department of Tumor Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Garncarska 11, 31-115 Cracow, Poland
2
Department of Radiotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Garncarska 11, 31-115 Cracow, Poland
3
Department of Radiotherapy for Children and Adults, University Children’s Hospital of Cracow, Wielicka 265, 30-663 Cracow, Poland
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2023, 13(2), 361; https://doi.org/10.3390/jpm13020361
Submission received: 11 January 2023 / Revised: 14 February 2023 / Accepted: 16 February 2023 / Published: 18 February 2023
(This article belongs to the Special Issue Personalized Medicine in Head and Neck Cancer)
Browse Figure
Review Reports Versions Notes

Abstract

:
Regarding attempts to find de-escalation methods of treatment for patients with HPV16-positive squamous cell carcinoma of the oropharynx (OPSCC), there is an urgent need to identify new prognostic factors which allow physicians to differentiate the prognosis of these patients. The aim of the study is to compare the incidence of transcriptionally active HPV16 infection and its type as well as other epidemiological, clinical, and histopathological features between SCC of the base of the tongue (BOTSCC) and tonsils (TSSCC). The analysis was performed in a group of 63 patients with OPSCC, for which, in our earlier studies, we assessed transcriptionally active HPV16 infection and its type (viral load and viral genome status). Transcriptionally active HPV16 infection was significantly more common in TSSCC (96.3%) than in BOTSCC (3.7%). Patients with TSSCC had significantly higher disease-free survival rates (84.1%) than those with BTSCC (47.4%); the same was true in the subgroup with HPV16 positivity. The obtained results are an important indication for further research on the development of new prognostic and/or predictive factors for patients with HPV16-positive squamous cell carcinomas of the oropharynx.

1. Introduction

Head and neck tumors (HN) are located in the upper gastrointestinal and respiratory tract, mostly in the oral cavity, oropharynx, and larynx. Around 95% of these tumors are squamous cell carcinomas (SCC). Heavy smoking, betel chewing, alcohol consumption, and human papillomavirus (HPV) infection are listed as the main etiological factors for these tumors. HPV infection (mainly HPV16) applies particularly in the case of squamous cell carcinomas of the oropharynx (OPSCC), which includes cancers localized on the base of the tongue, tonsils, soft palate, and pharyngeal wall. Over the last several years, an increase in incidence rates for SCC of the tonsil (TSSCC) and base of tongue (BOTSCC) has been observed, which is probably related to the increased number of HPV infections in these anatomical sites [1].
Numerous clinical studies have revealed that patients with HPV16-dependent OPSCC have a better prognosis than uninfected patients ([2]—review). These results inspired the impulse to undertake clinical trials into the possibility of de-escalation of anti-cancer treatment in patients with HPV16-dependent OPSCC in order to avoid toxic reactions after cisplatin or/and radiotherapy treatment. In these studies, various de-escalation strategies were or are still being tested, such as a decrease of the dose of radiotherapy (RT), reduction of the irradiation area, replacement of cisplatin (CisPt) during concurrent chemoradiotherapy (CRT) with less toxic systemic agents (e.g., cetuximab), or selection of patients for concurrent adjuvant chemoradiotherapy based on the results of induction chemotherapy ([3]—review). However, in two completed phase III clinical trials (RTOG 1016 and De-ESCALaTE) concerning randomly assigned patients with HPV16-dependent OPSCC for radiotherapy with concurrent cetuximab or CisPt, a significantly better OS) and higher local cure rate were observed in the CisPt arm [4,5]. In light of these results, it should be noticed that in more than 40% of patients with HPV16 positive OPSCC, progression of cancer disease is noted [6,7,8,9]. In addition, in the aforementioned clinical trials on de-escalation of treatment, de-intensification schemes were applied for all patients with viral infections. Therefore, further improvement of treatment outcomes may be related to the possibility of differentiating the prognosis of patients with HPV16-dependent OPSCC and, thus, the need to develop new prognostic and/or predictive factors. These factors would allow physicians to distinguish patients with viral infections that have a better prognosis (for whom treatment de-escalation should be applied) and those who have a worse prognosis (for which de-escalation of treatment is not possible).
Currently, there are attempts to select patients with OPSCC with HPV positivity for de-escalation treatment. Both clinical and biological features are taken into account. With regard to clinical features, the following ones are considered to be risk factors: clinical advancement stages T4 and N3, bilateral lymph node involvement, high level of smoking, and no response to induction chemotherapy [10,11]. In turn, few preclinical studies have shown that the presence of mutations in phosphatidylinositol 3-kinase gene [12], overexpression of the phosphorylated form of AKT protein kinase (Thr308) [12], lack of estrogen overexpression [13] and high level of mutant-allele tumor heterogeneity [14,15] are associated with a worse prognosis of OPSCC patients with HPV16 infection. In our earlier report on the subgroup of patients with HPV16-positive OPSCC, we also found a lack of CD44 overexpression and a lack of Sox-2 overexpression as independent positive prognostic factors, whereas in the HPV16 negative subgroup, these features had no prognostic potential [16]. In turn, the meta-analysis of Ndiaye et al. [17] has shown a slightly higher prevalence of HPV infection in TSSCC (53.9%) compared to BOTSCC (47.8%). A recent report also suggests that there are differences in epidemiological and clinical features (age, gender, race, facility, TN stages) between BOTSCC and TSSCC [18]. In the literature on the subject, to the best of our knowledge, there are no studies on the differences in the occurrence of a specific type of HPV16 infection (distinguished by viral genome state: integrated vs. episomal vs. mixed and the viral load (VL—the number of viral copies per cell)) between BOTSCC and TSSCC, while their demonstration may contribute to the optimization of treatment for patients with HPV16-positive OPSCC.
In our earlier studies on the group of 63 patients, we assessed transcriptionally active HPV16 infection (based on analysis of P16 expression and HPV16 DNA presence) [12] and its type (viral genome state and VL) [19]. In this group, active HPV 16 infection was noticed in 27 OPSCC (42.9%). It should be noted that detection of HPV infection based only on the analysis of virus DNA or P16 expression may lead to obtaining false positive results. HPV DNA presence does not indicate whether HPV is transcriptionally active or not. P16, in turn, is a surrogate marker indicating active HPV infection, but its overexpression may not exactly match the HPV DNA because it may also be caused by other non-viral factors. Among the 63 tumors, those with mixed states of genomes (70.4%) and higher VL (63.0% > 6764.3 viral copies/cell) prevailed. Thus, the main aim of the present study is to compare the frequency of transcriptionally active HPV16 infection and its type as well as epidemiological, clinical, and histopathological features between BOTSCC and TSSCC in the group of 63 patients with OPSCC.

2. Materials and Methods

2.1. Study Design

This study was performed on a group of 63 patients with squamous cell carcinoma of the oropharynx included in the analysis according to the following criteria: (1) SCC of the oropharynx, (2) lack of previous cancer treatment, (3) no distant metastases at the time of diagnosis and (4) follow-up time no shorter than 5 years until the end of 2019. The research was conducted based on formalin-fixed and paraffin-embedded tumor tissue fragments (FFPE) obtained for each patient prior to the initiation of cancer treatment. Before cutting for DNA isolation and immunohistochemistry, all blocks have undergone histopathological verification based on eosin/hematoxylin-stained slides to confirm the histological diagnosis, grade, and degree of keratinization. For further analysis, histopathologists indicated paraffin blocks with at least 50% of tumor neoplasm. All other details concerning inclusion and exclusion criteria as well as histopathological verification, were presented earlier [12].

2.2. DNA Extraction

DNA was extracted from 4 µm thick 3–5 sections using ReliaPrep FFPE gDNA Miniprep System (Promega, WI, USA) according to manufacturer suggestions with our own modification concerning prolongation of digestion at 56 °C from 1 h to overnight to provide improved quantity and quality of DNA. Deparaffinization was performed using mineral oil at 80 °C. After adding lysis buffer and centrifugation, the sample was digested with Proteinase K. Samples were further incubated for 1 h at 80 °C, digested with RNase A, and mixed with BL buffer and 96% ethanol. After centrifugation, the entire aqueous phase containing DNA was transferred into the binding column, washed twice, and finally eluted. DNA concentration and purity (measured as A260/280 and A260/230 ratios) were evaluated spectrophotometrically with Biophotometer Plus (Eppendorf, Germany). Samples were stored at −20 °C until used. A more detailed description of this procedure was presented earlier [20].

2.3. Assessment of Transcriptionally Active HPV16 Infection

To screen OPSCC samples for the presence of HPV DNA, nested PCR was applied, which consisted of two successive PCR runs, and the product of the first reaction with PGMY09/PGMY11 serves as a template in the second run with GP5+/GP6+. PGMY09/PGMY11 primers allow the amplification of the L1 gene fragment of multiple HPV types simultaneously, however, without indication of virus type precisely. A full list of primer sequences as well as all details concerning the composition of the reaction mixture or parameters of PCR runs, were reported earlier [12]. Negative (water) and positive (DNA isolated from HPV-positive cervical cancer tissue) controls were added to each run. The final products were separated in 2% agarose gel and visualized under UV light using SimplySafe dye (EURx, Poland). For each tumor, three independent analyses were performed, and a sample was classified as HPV DNA positive when at least one positive signal was observed.
HPV genotyping was performed for samples classified as HPV DNA positive in nested PCR. Genotyping was performed using AmoyDx Human Papillomavirus (HPV) Genotyping Detection Kit (Amoy Diagnostics Co., Xiamen, China) and quantitative PCR (qPCR). This assay identifies 19 high-risk HPV DNA (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82) and two low-risk HPV DNA (6 and 11). The procedure was performed according to the suggestions of the manufacturer. More details about this procedure are described by us earlier [12].
P16 immunostaining was performed in the subgroup of HPV16-positive tumors using CINtec® Histology Kit (Roche, Heidelberg, Germany) according to the manufacturer’s procedure described by us earlier [19]. In brief, 4 µm thick sections of FFPE HNSCC tissues were deparaffinized and hydrated through a series of xylenes and alcohols. After antigen unmasking (96 °C, 10 min) and exogenous peroxidases quenching (5 min), sections were incubated with primary anti-P16 antibody (clone E6H4, RT, 30 min) followed by 30 min incubation with visualization system. P16 was visualized using 3,3′–diaminobenzidine, and for nuclear counterstaining, hematoxylin was applied. Cervical cancer tissue with P16 overexpression was used as a positive control. For negative control, the primary antibody was omitted. Immunopositivity was defined according to Lewis et al. [21] as follows: >75% of positive staining cells or >50% staining with >25% confluent areas of positive staining.
Tumors were defined as those with transcriptionally active HPV16 infection if they contained HPV DNA (detected during nested PCR and then confirmed by genotyping assay) and overexpressed P16 (according to immunohistochemistry). All other cases (HPV DNA+/P16−, HPV DNA−/P16+, and HPV DNA−/P16−) were classified as those lacking a transcriptionally active HPV16 infection [12].

2.4. Assessment of Viral Load and Viral Genome Status

HPV16 VL and the type of its genome state were determined by qPCR. For VL analysis, two standard curves were obtained. One of them concerns Ct for a 139-bp fragment of β-actin gene in serial 10-fold dilutions of the reference human genomic DNA (Roche Diagnostics, GmbH, Germany) vs. the number of gene copies to obtain the number of cells in the sample. The second one concerns Ct for HPV16 E6 in serial 10-fold dilutions of the HPV16 plasmid (ATCC, USA) vs. the number of gene copies to obtain the number of HPV16 copies in the sample. HPV16 VL was calculated as the number of virus copies per cell, assuming that two copies of the β-actin gene correspond to one cell. All other details concerning these procedures were presented earlier [19].
Physical HPV16 genome state (episomal, integrated, mixed) was analyzed on the basis of the CtE2/CtE6 ratio. The viral genome was regarded as integrated when the CtE2/CtE6 was 0, as episomal when this ratio was 1 or more, and as mixed when the CtE2/CtE6 was between 0 and 1 as we described earlier [22].

2.5. Statistical Analysis

Descriptive statistics were used to determine the mean and median values of continuous variables and standard errors of means (SE). Associations between categorical variables were analyzed using the Pearson Chi-square test. In survival analysis, as an endpoint, disease-free survival was applied as a time from the end of therapy until the first documented evidence of recurrent disease—treatment failure, locoregional recurrence, distant metastasis, within 5 years after completing the treatment. In this analysis, differences between subgroups were tested by the log-rank test. All statistical tests were two-sided, and p < 0.050 was considered significant. Statistical analyses were carried out using the Statistica program, version 13.0.

3. Results

3.1. Clinical Characteristics of a Group of 63 Patients with Squamous Cell Carcinoma of the Oropharynx

The subgroup of 63 patients with OPSCC included 15 women (23.8%) and 48 men (76.2%) aged from 38 to 75 years, with a mean of 57.5 years ± 1.2 (SE) (Table 1). In the analyzed group, T3 (50.8%), N2 (55.6%), non-keratinized (55.6%), and G2 tumors (52.4%) predominated. The majority of patients were treated with CRT-CisPt (n = 28, 44.4%), either alone (n = 22, 78.6%) or after surgery (n = 6, 21.4%). In 19 patients (30.2%), radiotherapy was used alone (n = 6, 31.6%) or adjuvantly after surgery (n = 13, 23.3%), while 16 patients (25.4%) were treated with chemotherapy induction (CisPt + 5-fluorouracil + taxanes), followed by ionizing radiation. The decision regarding the operation was made by a team of physicians consisting of a surgeon, radiotherapist, and chemotherapist, who referred for the surgery patients with advanced disease (T ≥ 3) and histological grade G1. A detailed description of the treatment, doses of cisplatin, and RT can be found in our earlier publications [12].
For 63 patients, the mean follow-up time was 42.0 months ± 4.4 and ranged from 0 to 113 months. At the time of the study, 45 patients (71.4%) had regressed, and 18 (28.6%) had progression (2 failures, 12 local recurrences, and 4 distant metastases) 0 to 39 months after completion of the study.

3.2. Differences between Squamous Cell Carcinoma of Base of Tongue and Tonsil in Epidemiological, Clinical, and Histopathological Features as Well as Prevalence of HPV16 Infection and Its Type

In the group of 63 patients, tonsil cancers predominated (n = 44, 69.8%) (Table 1). Among patients with TSSCC, female gender, lower clinical stage T (T2 and T3), and lack of keratinization were significantly more frequent as compared to BOTSCC. TSSCC patients were also characterized by a higher rate of cancer regression at 5 years after completing the oncological treatment (80.0%) than patients with BOTSCC (20.0%). There were no other statistically significant differences between SCCTS and SCCBOT in terms of the rest of the analyzed epidemiological, clinical, and histopathological features.
In the group of 63 OPSCC, transcriptionally active HPV16 infection was present in 27 tumors (42.9%), and it was significantly more common in TSSCC (96.3%) than in BOTSCC (3.7%) (Table 1). One patient with BOTSCC and HPV16 infection was a woman, 60 years old, with Karnofsky scale <80%, T3, N2 stages and grade G2, addicted to alcohol and smoking, treated by surgery and adjuvant RT, who developed distant metastases 15 months after completing the treatment. All cancers with a higher VL (median > 6764.3 virus copies per cell) were TSSCC, and all BOTSCC had VL equal to or below the median. There was no significant difference between BOTSCC and TSSCC according to the frequency of specific status of the HPV16 genome (integrated vs. mixed).
In the group of 63 patients with HNSCC, the 5-year DFS was 66.3%. Patients with TSSCC had significantly higher DFS (84.1%) than those with BOTSCC (47.4%) (Table 2, Figure 1). All, except one, TSCC patients with transcriptionally active HPV16 infection survived 5 years without cancer progression (96.1%), whereas, for one patient with BOTSCC and this infection, cancer progression (distant metastasis) was observed at the 15th month after completing the treatment. In the subgroup of HNSCC patients without HPV16 presence, localization of the tumor did not significantly influence DFS.

4. Discussion

To the best of our knowledge, this is the first report showing the difference in the level of viral load between the SCC of the base of the tongue and the tonsils.
We have namely shown the significantly increased frequency of cancers with higher VL among TSSCC compared to BOTSCC (Table 1). Moreover, in TSSCC, a significantly higher incidence of transcriptionally active HPV16 infection (Table 1) and better disease-free survival (Table 2) were noticed. This result suggests better DFS for TSSCC patients with transcriptionally active HPV16 infection than for BOTSCC patients with this infection. In fact, in HNSCC patients with HPV16 positivity, tumor localization had a significant impact on DFS (Table 2), although this result should be treated with caution because there was only one patient with BOTSCC and HPV16 infection. However, these results are in line with those obtained by us earlier [19] and other authors [17]. Referring to VL, in our earlier analysis concerning the group of 36 patients with HPV16-positive HNSCC, significantly better OS and DFS for patients with higher VL were shown [19]. As we now know today, the vast majority of these patients suffered from tonsillar cancers. In turn, a higher prevalence of HPV in TSSCC than in BOTSCC is in accordance with the results of many studies, which were summarized in the meta-analysis of Ndiaye et al. [17], in which 148 publications were included. In this meta-analysis, the percentage of HPV prevalence in TSSCC was 53.9%, whereas, in BOTSCC, it was 47.8%. The percentage concerning BOTSCC is much higher than this obtained by us (3.7%). However, we analyzed a much lower number of patients and only transcriptionally active HPV16 infection, whereas the above-mentioned analysis concerns different types of HR-HPV and different methods of HPV DNA detection.
There are three important questions that should be discussed in the context of these results: (1) why HPV infection is noticed more often in the tonsils than in the base of the tongue, (2) why HPV16 infection in the tonsils is characterized by higher VL as compared to BOTSCC and (3) why TSSCC are characterized by better prognosis than BOTSCC. Results of some studies suggest that the answer to all these questions may be related to differences in the functioning of the immune system between BOTSCC and TSSCC. Recently, Chen et al. [23] interrogated the TCGA HNSCC data and distinguished a subgroup of patients referred to as the “active immune class” associated with oropharyngeal tumors, T cell-inflamed signature, and the presence of HPV. Unfortunately, they did not report data concerning the subsite of HNSCC. In turn, Welters et al. [24] detailed the immune compartment in OPSCC with HPV16 positivity. In 64% HPV16-positive tumors, they indicated the presence of type I specific T-cells as well as higher numbers of activated CD161+ T cells, CD103+, CD103+ tissue-resident T cells, dendritic cells, and DC-like macrophages. In their study, HPV16-positive tumors with specific T-cells had better OS and lower T and N stages. Although they did not differentiate subgroups with BOTSCC and TSSCC, in the light of present results, it can be assumed that patients with cancers characterized by the presence of type I specific T-cells suffer rather from TSSC than from BOTSCC. In regard to higher VL noticed for TSSCC than for BOTSCC in the present study, some reports have found significant correlations between higher VL and overproduction of circulating antibodies against plasma virus-like particles or antibodies against HPV16 oncoproteins E6 and E7 [25] and between higher VL and expression of HPV E6/E7 mRNA [26,27,28]. All these facts may suggest that in TSSCC, transcriptionally active HPV infection and the same higher VL may be related to additional stimulation of immune response. This particular stimulation in TSSCC may indicate an anatomical distinction between TSSCC and BOTSCC. A recent study has shown that the tonsils are comprehensive sources of extrathymic T-cell development and also sites for the development of innate immune cells known as group 3 innate lymphoid cells (ILC3) [29]. These cells are unique to the lamina propria and tonsils and probably constitute an important first line of defense against viral infections. BOT tissue harbors mucus glands which drain directly into crypts rather than the surface. Additionally, crypts are shallower with less complex branching compared with the crypts in palatine tonsils, which may reflect a different immunologic milieu or structure as well [15]. However, contrary to the suggestion about more effective stimulation of the immune system in TSSCC, it was revealed that OPSCC with HPV infection were more likely to be B7-H1 positive (B7-H1 is involved in B7-H1/PD-1 signaling pathway of host immune suppression), what allows to avoid inflammatory immune responses [30].
In the present study, we have shown a better rate of disease-free survival for patients with TSSCC than for those with BOTSCC. This result is in accordance with results obtained by other authors, which directly compared survival in these two localizations. An analysis by Windon et al. [18] revealed a worse-than-expected prognosis for node-negative patients with HPV-positive BOTSCC. Welters et al. [24] have found better OS for patients with HPV16-positive OPSCC and with the presence of type I specific T-cells, who, as we explained above, probably have TSSCC. These results can be partly explained by a more effective immune system in TSCC than in BOTSCC. However, considering the reasons for a better prognosis of patients with TSSCC than with BOTSCC, it is worth paying attention to the differences between these two localizations in clinical features. In the present study, we have found a higher number of female patients with lower T stages (T2 + 3) among TSSCC compared to BOTSCC. However, we did not notice a difference in the distribution of patients with specific N stages between TSSCC and BOTSCC. In turn, one patient with BOTSCC and HPV16 infection, a woman, 60 years old, with Karnofsky scale < 80%, T3, N2 stages and grade G2, addicted to alcohol and smoking, treated by surgery and adjuvant RT, developed distant metastases 15 months after completing the treatment. These results are partly consistent with those of other authors. Welters et al. [24] revealed lower T and N stages in the cases of patients with cancer type I specific T-cells. In turn, Windon et al. [18], who analyzed 13,081 HPV-positive BOT and 16,874 HPV-positive TS cancers, have shown that patients with HPV-positive BOTSCC were also more frequently male and white and tended to have more advanced TN stages as compared to patients with TSSCC. Contrary to us, these authors did not notice significant differences between these two localizations in the percentage of HPV positivity.
An important limitation of the current study is the small number of patients included in the analysis, as discussed earlier. However, we believe that the presented results present an important signal to study the differences in biology and clinical features between squamous cell carcinomas of the base of the tongue and the tonsils in a greater number of patients. Experimental studies are needed in order to explain the mechanisms concerning the potential differences between these two localizations. Experimental studies are needed in order to explain mechanisms concerning the potential differences between these two localizations. Confirmation of our results in a larger group of patients as well as an indication of biological mechanisms of obtained results, may contribute to the individualization of treatment in OPSCC patients and the use of de-escalation of treatment only in the HPV-positive OSCC group with good prognosis.

5. Conclusions

To conclude, due to the relatively small number of 63 patients with SCC of the oropharynx, the present study should be considered a pilot study. However, obtained differences in the biological (in the frequency of HPV infection and the level of viral load) and clinical features between squamous cell carcinomas of the base of the tongue and tonsil may be an important indication for further studies concerning the development of new prognostic and/or predictive factors for patients with HPV16-positive cancers of the oropharynx.

Author Contributions

Conceptualization, B.B., A.M.-M. and K.M.; methodology, B.B., A.J.-W., A.M.-M.; investigation, B.B. and A.J.-W.; data curation, A.M.-M. and K.M.; writing, B.B.; writing-review and editing, A.M.-M., A.J.-W. and K.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethical Committee at the Regional Medical Chamber in Cracow (Poland) on 16 February 2017 (5/KBL/OIL/2017).

Informed Consent Statement

During the study, direct contact with patients nor use of their personal data were necessary because the study was not intended to modify the diagnostic or treatment procedures. Therefore, no informed consents from patients were required. All samples were anonymized.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declared no potential conflict of interest with respect to the research, authorship and/or publication of this article.

References

  1. Jordan, K.H.; Fisher, J.L.; Paskett, E.D. Distinct sociodemographic differences in incidence and survival rates for human papillomavirus (HPV)-like, non-HPV-like, and “other”-like oral cavity and pharynx cancers: An analysis of Surveillance, Epidemiology and End Results (SEER) Program data. Front. Oncol. 2022, 12, 980900. [Google Scholar] [CrossRef]
  2. Maxwell, J.H.; Grandis, J.R.; Ferris, R.L. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annu. Rev. Med. 2016, 67, 91–101. [Google Scholar] [CrossRef] [Green Version]
  3. Rosenberg, A.J.; Vokes, E.E. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. Oncol. 2021, 26, 40–48. [Google Scholar] [CrossRef]
  4. Mehanna, H.; Robinson, M.; Hartley, A.; Kong, A.; Foran, B.; Fulton-Lieuw, T.; Dalby, M.; Mistry, P.; Sen, M.; O’Toole, L.; et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet 2019, 393, 51–60. [Google Scholar] [CrossRef] [Green Version]
  5. Gillison, M.L.; Trotti, A.M.; Harris, J.; Eisbruch, A.; Harari, P.M.; Adelstein, D.J.; Jordan, R.C.K.; Zhao, W.; Sturgis, E.M.; Burtness, B.; et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet 2019, 393, 40–50. [Google Scholar] [CrossRef]
  6. Dayyani, F.; Etzel, C.J.; Liu, M.; Ho, C.-H.; Lippman, S.M.; Tsao, A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010, 2, 15. [Google Scholar] [CrossRef] [Green Version]
  7. Liu, H.; Li, J.; Zhou, Y.; Hu, Q.; Zeng, Y.; Mohammadreza, M.M. Human papillomavirus as a favorable prognostic factor in a subset of head and neck squamous cell carcinomas: A meta-analysis. J. Med. Virol. 2016, 89, 710–725. [Google Scholar] [CrossRef]
  8. O’Rorke, M.A.; Ellison, M.V.; Murray, L.J.; Moran, M.; James, J.; Anderson, L.A. Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis. Oral Oncol. 2012, 48, 1191–1201. [Google Scholar] [CrossRef]
  9. Ragin, C.C.R.; Taioli, E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. Int. J. Cancer 2007, 121, 1813–1820. [Google Scholar] [CrossRef]
  10. Marur, S.; Li, S.; Cmelak, A.J.; Gillison, M.L.; Zhao, W.J.; Ferris, R.L.; Westra, W.H.; Gilbert, J.; Bauman, J.E.; Wagner, L.I.; et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group. J. Clin. Oncol. 2017, 35, 490–497. [Google Scholar] [CrossRef] [Green Version]
  11. Alotaibi, M.; Valova, V.; Hänsel, T.; Stromberger, C.; Kofla, G.; Olze, H.; Piwonski, I.; Albers, A.; Ochsenreither, S.; Coordes, A. Impact of Smoking on the Survival of Patients With High-risk HPV-positive HNSCC: A Meta-analysis. Vivo 2021, 35, 1017–1026. [Google Scholar] [CrossRef]
  12. Janecka-Widła, A.; Majchrzyk, K.; Mucha-Małecka, A.; Słonina, D.; Biesaga, B. Prognostic potential of Akt, pAkt(Ser473) and pAkt(Thr308) immunoreactivity in relation to HPV prevalence in head and neck squamous cell carcinoma patients. Pathol. Res. Pract. 2021, 229, 153684. [Google Scholar] [CrossRef]
  13. Kwon, S.; Ahn, S.-H.; Jeong, W.-J.; Jung, Y.H.; Bae, Y.J.; Paik, J.H.; Chung, J.-H.; Kim, H. Estrogen receptor α as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma. J. Transl. Med. 2020, 18, 240. [Google Scholar] [CrossRef]
  14. Mroz, E.A.; Rocco, J.W. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013, 49, 211–215. [Google Scholar] [CrossRef] [Green Version]
  15. Mroz, E.A.; Tward, A.D.; Pickering, C.R.; Myers, J.N.; Ferris, R.L.; Rocco, J.W. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 2013, 119, 3034–3042. [Google Scholar] [CrossRef]
  16. Kołodziej-Rzepa, M.; Biesaga, B.; Janecka-Widła, A.; Mucha-Małecka, A. Lack of CD44 and Sox-2 Overexpression as Two Independent Favourable Prognostic Factors in HPV Positive Patients with Oropharyngeal Cancers. Pathobiology 2022, 89, 205–219. [Google Scholar] [CrossRef]
  17. Ndiaye, C.; Mena, M.; Alemany, L.; Arbyn, M.; Castellsagué, X.; Laporte, L.; Bosch, F.X.; de Sanjosé, S.; Trottier, H. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. Lancet Oncol. 2014, 15, 1319–1331. [Google Scholar] [CrossRef]
  18. Windon, M.J.; Fakhry, C.; Margalit, D.N.; Dey, T.; Rettig, E.M. Epidemiologic distinctions between base of tongue and tonsil oropharyngeal carcinomas. Head Neck 2021, 43, 3076–3085. [Google Scholar] [CrossRef]
  19. Biesaga, B.; Mucha-Małecka, A.; Janecka-Widła, A.; Kołodziej-Rzepa, M.; Szostek, S.; Słonina, D.; Kowalczyk, A.; Halaszka, K.; Przewoźnik, M. Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16. J. Cancer Res. Clin. Oncol. 2018, 144, 63–73. [Google Scholar] [CrossRef] [Green Version]
  20. Biesaga, B.; Janecka, A.; Mucha-Małecka, A.; Adamczyk, A.; Szostek, S.; Słonina, D.; Halaszka, K.; Przewoźnik, M. HPV16 detection by qPCR method in relation to quantity and quality of DNA extracted from archival formalin fixed and paraffin embedded head and neck cancer tissues by three commercially available kits. J. Virol. Methods 2016, 236, 157–163. [Google Scholar] [CrossRef]
  21. Lewis, J.S.; Chernock, R.D.; Ma, X.-J.; Flanagan, J.J.; Luo, Y.; Gao, G.; Wang, X.; El-Mofty, S.K. Partial p16 staining in oropharyngeal squamous cell carcinoma: Extent and pattern correlate with human papillomavirus RNA status. Mod. Pathol. 2012, 25, 1212–1220. [Google Scholar] [CrossRef] [Green Version]
  22. Biesaga, B.; Szostek, S.; Klimek, M.; Jakubowicz, J.; Wysocka, J. Comparison of the sensitivity and specificity of real-time PCR and in situ hybridization in HPV16 and 18 detection in archival cervical cancer specimens. Folia Histochem. Cytobiol. 2012, 50, 239–247. [Google Scholar] [CrossRef] [Green Version]
  23. Chen, Y.-P.; Wang, Y.-Q.; Lv, J.-W.; Li, Y.-Q.; Chua, M.L.K.; Le, Q.-T.; Lee, N.; Colevas, A.D.; Seiwert, T.; Hayes, D.N.; et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: Implications for immunotherapy. Ann. Oncol. 2019, 30, 68–75. [Google Scholar] [CrossRef]
  24. Welters, M.J.; Ma, W.; Santegoets, S.J.; Goedemans, R.; Ehsan, I.; Jordanova, E.S.; van Ham, V.J.; van Unen, V.; Koning, F.; van Egmond, S.I.; et al. Intratumoral HPV16-Specific T Cells Constitute a Type I–Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer. Clin. Cancer Res. 2018, 24, 634–647. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kreimer, A.R.; Clifford, G.M.; Snijders, P.J.; Castellsagué, X.; Meijer, C.J.; Pawlita, M.; Viscidi, R.; Herrero, R.; Franceschi, S. International Agency for Research on Cancer (IARC) Multicenter Oral Cancer Study Group. HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int. J. Cancer 2005, 115, 329–332. [Google Scholar] [CrossRef] [PubMed]
  26. Deng, Z.; Hasegawa, M.; Kiyuna, A.; Matayoshi, S.; Uehara, T.; Agena, S.; Yamashita, Y.; Ogawa, K.; Maeda, H.; Suzuki, M. Viral load, physical status, and E6/E7 mRNA expression of human papillomavirus in head and neck squamous cell carcinoma. Head Neck 2013, 35, 800–808. [Google Scholar] [CrossRef] [PubMed]
  27. Holzinger, D.; Schmitt, M.; Dyckhoff, G.; Benner, A.; Pawlita, M.; Bosch, F.X. Viral RNA Patterns and High Viral Load Reliably Define Oropharynx Carcinomas with Active HPV16 Involvement. Cancer Res 2012, 72, 4993–5003. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Jung, A.C.; Briolat, J.; Millon, R.; de Reyniès, A.; Rickman, D.; Thomas, E.; Abecassis, J.; Clavel, C.; Wasylyk, B. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int. J. Cancer 2010, 126, 1882–1894. [Google Scholar] [CrossRef] [PubMed]
  29. McClory, S.; Hughes, T.; Freud, A.G.; Briercheck, E.L.; Martin, C.; Trimboli, A.J.; Yu, J.; Zhang, X.; Leone, G.; Nuovo, G.; et al. Evidence for a stepwise program of extrathymic T cell development within the human tonsil. J. Clin. Investig. 2012, 122, 1403–1415. [Google Scholar] [CrossRef]
  30. Ukpo, O.C.; Thorstad, W.L.; Lewis, J.S. B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. Head Neck Pathol. 2013, 7, 113–121. [Google Scholar] [CrossRef] [Green Version]
Jpm 13 00361 g001 550
Figure 1. Kaplan–Meier curves concerning disease-free survival stratified by localization of tumors in the group of 63 patients with squamous cell carcinomas of the oropharynx and into two subgroups identified by the prevalence of transitionally HPV16 infection.
Figure 1. Kaplan–Meier curves concerning disease-free survival stratified by localization of tumors in the group of 63 patients with squamous cell carcinomas of the oropharynx and into two subgroups identified by the prevalence of transitionally HPV16 infection.
Jpm 13 00361 g001
Table
Table 1. Epidemiological, clinical, and histopathological features in the subgroups of patients with squamous cell carcinoma of base of tongue and tonsil.
Table 1. Epidemiological, clinical, and histopathological features in the subgroups of patients with squamous cell carcinoma of base of tongue and tonsil.
All (%) 1Localization of Squamous Cell Carcinoma
Base of Tongue
n (%) 2		Tonsil n (%)Test χ 2 p *
All63 (100.0)19 (30.2)44 (69.8)
Age
  ≤58 years 336 (57.1)12 (33.3)24 (66.7)
  >58 years27 (42.9)7 (25.9)20 (74.1)0.526
Gender
  Female15 (23.8)1 (6.7)14 (93.3)
  Male48 (76.2)18 (37.5)30 (62.5)0.023
Status in the Karnofsky scale
  <80%26 (41.3)6 (23.1)20 (76.9)
  ≥80%37 (58.7)13 (35.1)24 (64.9)0.304
The level of smoking-Brinkman index 4
  ≤520 334 (54.0)8 (23.5)26 (76.5)
  >52029 (46.0)11 (37.9)18 (62.1)0.214
The level of drinking 5
  Low28 (44.4)5 (17.9)23 (82.1)
  High35 (55.6)14 (40.0)21 (60.0)0.057
T stage
  215 (23.8)4 (26.7)11 (73.3)
  332 (50.8)7 (21.9)25 (78.1)
  416 (25.4)8 (50.0)8 (50.0)0.045
N stage
  010 (15.9)5 (50.0)5 (50.0)
  113 (20.6)2 (15.4)11 (84.6)
  2 + 340 (63.5)12 (30.0)28 (70.0)0.971
Grade
  125 (39.7)7 (28.0)18 (72.0)
  2 + 338 (60.3)12 (31.6)26 (68.4)0.762
Keratinization
  Yes35 (44.4)16 (45.7)19 (54.3)
  No28 (55.6)3 (10.7)25 (89.3)0.003
Transcriptionally active HPV16 infection
  Yes27 (42.9)1 (3.7)26 (96.3)
  Not36 (57.1)18 (50.0)18 (50.0)0.000
P16 immunopositivity
  Yes27 (42.9)7 (25.9)20 (74.1)
  Not36 (57.1)20 (55.6)16 (44.4)0.019
Viral load (only in HPV16 positive, n = 27)
  >6764.3 copies/cell 317 (63.0)0 (0.0)17 (100.0)
  ≤6764.3 copies/cell10 (37.0)4 (40.0)6 (60.0)0.024 *
Physical genome status (only in HPV16 positive, n = 27)
  Integrated8 (29.6)0 (0.0)8 (100.0)
  Mixed19 (70.4)4 (21.1)15 (78.9)0.508
Treatment
  Definitive CisPt-CRT or surgery + CisPt-CRT28 (44.4)4 (14.3)24 (85.7)
  Definitive RT or surgery + RT19 (30.2)8 (42.1)11 (57.9)
  Induction CT + definitive RT16 (25.4)7 (43.7)9 (56.3)0.058
Treatment outcome
  Regression of cancer disease45 (71.4)9 (20.0)36 (80.0)
  Treatment failure2 (3.2)1 (50.0)1 (50.0)
  Local recurrence12 (19.1)7 (58.3)5 (41.7)
  Distant metastases2 (6.3)1 (50.0)1 (50.0)0.049
Survival
  Alive at the last follow-up34 (54.0)3 (8.8)31 (91.2)
  Death from cancer disease15 (20.0)9 (60.0)6 (40.0)
  Death from other reasons14 (35.7)7 (50.0)7 (50.0)0.000
Abbreviations: CisPt-CRT, concurrent chemoradiotherapy with cisplatin; CT, chemotherapy; 1 Column percentage; 2 Row percentage; 3 Median value; 4 Number of cigarettes per day × years of smoking; 5 Low level of drinking—no alcohol and occasional drinkers (at most two drinks a day, especially with a meal) high level of drinking—more than 15 drinks high percentage alcohol in a week and alcoholics; * The statistical significance limit for p value was accepted as p < 0.05, significant results are written in bold font.
Table
Table 2. 5-year disease-free survival in the group of 63 patients with squamous cell carcinoma of the head and neck and subgroup of 27 patients with transcriptionally active HPV16 infection according to tumor localization.
Table 2. 5-year disease-free survival in the group of 63 patients with squamous cell carcinoma of the head and neck and subgroup of 27 patients with transcriptionally active HPV16 infection according to tumor localization.
5-Year Disease Free Survival
Response
n (%)		HR95% CILog-Rank p
63 patients with squamous cell carcinoma of head and neck
  Base of tongue9/19 (47.4)5.1381.927–13.7060.001
  Tonsil37/44 (84.1)1.000
27 patients with squamous cell carcinoma of head and neck and transcriptionally active HPV16 infection
  Base of tongue0/1 (0.0)12.2201.378–25.2830.006
  Tonsil25/26 (96.1)1.000
36 patients with squamous cell carcinoma of head and neck and without transcriptionally active HPV16 infection
  Base of tongue9/18 (50.0%)2.3720.836–6.7320.102
  Tonsil12/18 (66.7)1.000
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Biesaga, B.; Mucha-Małecka, A.; Janecka-Widla, A.; Małecki, K. Differences between Squamous Cell Carcinomas of the Base of the Tongue and the Tonsils in Prevalence of HPV16 Infection, Its Type, and Clinical Features. J. Pers. Med. 2023, 13, 361. https://doi.org/10.3390/jpm13020361

AMA Style

Biesaga B, Mucha-Małecka A, Janecka-Widla A, Małecki K. Differences between Squamous Cell Carcinomas of the Base of the Tongue and the Tonsils in Prevalence of HPV16 Infection, Its Type, and Clinical Features. Journal of Personalized Medicine. 2023; 13(2):361. https://doi.org/10.3390/jpm13020361

Chicago/Turabian Style

Biesaga, Beata, Anna Mucha-Małecka, Anna Janecka-Widla, and Krzysztof Małecki. 2023. "Differences between Squamous Cell Carcinomas of the Base of the Tongue and the Tonsils in Prevalence of HPV16 Infection, Its Type, and Clinical Features" Journal of Personalized Medicine 13, no. 2: 361. https://doi.org/10.3390/jpm13020361

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop